secwatch.observer — SEC 8-K summary
======================================

Issuer:     Phio Pharmaceuticals Corp. (PHIO)
CIK:        0001533040
Form:       8-K
Filed at:   2022-11-10T23:59:59+00:00
Accession:  0001683168-22-007530
Event type: earnings
Sentiment:  neutral
Materiality: 0.65
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Phio Q3 net loss $3.6M, cash $14.5M; appoints Bitterman, Mahoney, Spellman
--------------------------------------------------------------------------

- New appointments: Robert Bitterman as Interim Executive Chairman, Linda Mahoney as VP of Project Development, Dr. Mary Spellman as medical advisor.
- Cash at Sept 30, 2022: $14.5M, down from $24.1M at Dec 31, 2021; expects to fund operations for at least 12 months.
- Net loss $3.6M ($0.26/share) vs $3.7M ($0.28) in Q3 2021; R&D expenses down 6% to $2.5M.
- Phase 1b study of PH-762 for advanced melanoma continues enrollment; top-line data expected Q1 2023.
- Plans to initiate trial with AgonOx in Q4 2022; IND-enabling studies for PH-894 by year end.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1533040/000168316822007530/0001683168-22-007530-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1533040/000168316822007530/phio_8k.htm
  HTML page:      https://secwatch.observer/filing/0001683168-22-007530

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer